VRTX Q1 2024 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

VRTXVertex Pharmaceuticals Incorporated

$129B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2.7B+13.2% YoY

Gross Profit

$2.3B87.3% margin

Operating Income

$1.1B42.4% margin

Net Income

$1.1B40.9% margin

EPS (Diluted)

$4.21

QoQ Revenue Growth

+6.7%

Cash Flow

Operating Cash Flow

$1.3B

Free Cash Flow

$1.1B

Stock-Based Comp.

$192M

Balance Sheet

Total Assets

$23.9B

Total Liabilities

$5.4B

Stockholders' Equity

$18.5B

Cash & Equivalents

$9.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.7B	$2.4B	+13.2%
Gross Profit	$2.3B	$2.1B	+11.2%
Operating Income	$1.1B	$779M	+46.3%
Net Income	$1.1B	$700M	+57.1%

Revenue Segments

TRIKAFTA/KAFTRIO

$2.5B100%

Geographic Segments

UNITED STATES

$1.5B56%

Europe

$967M36%

Other, Non U.S.

$203M8%